Brolucizumab Approved indication: macular degeneration

被引：1
作者：
不详
机构：
来源：
AUSTRALIAN PRESCRIBER | 2020年 / 43卷 / 04期
关键词：
D O I：
10.18773/austprescr.2020.045
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：133 / 134
页数：2
相关论文
共 3 条
  • [1] Treatment of age-related macular degeneration
    Bunting, Roland
    Guymer, Robyn
    [J]. AUSTRALIAN PRESCRIBER, 2012, 35 (03) : 90 - 93
  • [2] HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
    Dugel, Pravin U.
    Koh, Adrian
    Ogura, Yuichiro
    Jaffe, Glenn J.
    Schmidt-Erfurth, Ursula
    Brown, David M.
    Gomes, Andre, V
    Warburton, James
    Weichselberger, Andreas
    Holz, Frank G.
    [J]. OPHTHALMOLOGY, 2020, 127 (01) : 72 - 84
  • [3] Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial
    Dugel, Pravin U.
    Jaffe, Glenn J.
    Sallstig, Peter
    Warburton, James
    Weichselberger, Andreas
    Wieland, Mark
    Singerman, Lawrence
    [J]. OPHTHALMOLOGY, 2017, 124 (09) : 1296 - 1304
1